RNA-Based Therapies Usher in New Era for Cardiovascular Precision Medicine
Background
The current landscape of cardiovascular pharmacotherapy is rapidly evolving, particularly for conditions like heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and atherosclerotic cardiovascular disease. While established drug classes have significantly improved patient outcomes, there remains a critical need for more targeted, individualized treatments to further reduce morbidity and mortality. This review addresses how emerging drug classes and RNA-based technologies are shaping the future of cardiovascular precision medicine, moving beyond conventional approaches.
Results
The review highlighted several key advancements: for HFrEF, low-dose digitoxin is emerging as a potential fifth pillar alongside the established "fantastic four" therapies. For HFpEF and HFmrEF (heart failure with mildly reduced ejection fraction), sodium-glucose linked transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists are showing significant gains in morbidity and quality of life. Innovations also include myosin inhibitors for hypertrophic cardiomyopathy, de-escalated dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS), and factor XI inhibitors as a potentially safer anticoagulant with reduced bleeding risk. In prevention, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, including small interfering RNA (siRNA)-based approaches targeting lipoprotein(a), and RNA-based and aldosterone synthase-based hypertension therapy are paving the way. The most significant finding is the clear trajectory towards individualized cardiovascular precision medicine through RNA-based therapies, including siRNA for PCSK9 and lipoprotein(a), and microRNA targeting for hypertension.
Why It Matters
This review underscores the transformative potential of precision medicine in cardiology, moving beyond a one-size-fits-all approach. The integration of RNA-based therapies and novel drug classes promises to offer more effective and safer treatment options for a wide range of cardiovascular diseases. These advancements could lead to highly individualized treatment regimens, significantly improving patient outcomes and quality of life in clinical settings. Future steps will involve continued research, including Phase II and Phase III human trials, to validate the efficacy and safety of these emerging therapies and bring them into widespread clinical practice.